Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Ascending Single Oral Dose, Double-Blind, Randomized, Placebo-Controlled Study Assessing The Safety, Tolerability, and Pharmacokinetics of DSP-0187 in Healthy Adult Male Subjects

Next Previous
Search
Trial Profile

An Ascending Single Oral Dose, Double-Blind, Randomized, Placebo-Controlled Study Assessing The Safety, Tolerability, and Pharmacokinetics of DSP-0187 in Healthy Adult Male Subjects

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DSP 0187 (Primary)
  • Indications Narcolepsy; Sleep disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Sumitomo Pharma

    • Most Recent Events

    • 30 Nov 2023 According to a Jazz Pharmaceuticals, study achieved proof of concept in healthy volunteers based on the maintenance of wakefulness test but reported adverse effects of visual disturbances and cardiovascular effects in study participants, reported by Kelvin Tan, MB BCh, MRCPCH, during the 6th annual Evercore ISI HealthCONx Conference on Tuesday.
    • 09 May 2022 New trial record
    • 04 May 2022 According to a Jazz Pharmaceuticals plc media release, this trial was initiated in November 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top